Core Insights - The article discusses the confusion between atopic dermatitis (AD) and eczema, highlighting that AD is a specific type of eczema with distinct characteristics [1] - It emphasizes the prevalence of AD in China, with over 70 million patients, and the common misconceptions surrounding the disease [1] - The article outlines the importance of proper diagnosis and treatment methods for managing AD effectively [2][4] Group 1: Disease Understanding - Atopic dermatitis is characterized by chronic inflammation, severe itching, and recurrent episodes, with about 60% of patients also suffering from allergic rhinitis or asthma [1] - The disease has a significant familial aggregation, with a 50% chance of children developing AD if one parent is affected [1] - The "Zhang's criteria" for diagnosis requires meeting two out of three conditions: chronic or recurrent symmetrical eczema, personal or family history of allergies, and elevated serum IgE or eosinophils [1] Group 2: Treatment Approaches - The "three-dimensional anti-itch method" includes cold compresses, moisturizing creams, and medication, with innovative topical agents like Zeli Mei showing promising results [2] - Clinical data indicates that 61.5% of patients in an 8-week trial achieved complete clearance of skin lesions, with rapid itch relief observed within 2 hours [2] - The drug is priced significantly lower in China at 360 yuan compared to 1,400 USD in the U.S., easing the financial burden on patients [2] Group 3: Long-term Management - Active maintenance treatment is crucial, with recommendations for preventive use of Zeli Mei even after symptoms disappear, reducing the risk of recurrence by 60% [4] - Keeping a "itch diary" to track triggers such as temperature and diet is advised for better management of the condition [4] - The drug has been approved for use in children over 2 years old, showing over 80% clearance rate in clinical trials with minimal side effects [4]

顾军教授特别强调，泽立美作为非激素类创新药物，不仅疗效优异、复发风险低，尤其适合儿童患者 ——无刺激性、涂抹舒适、易于接受。同时，对于成人患者，其高效性和安全性同样令人满意。值得一 提的是，泽立美领先美国在中国率先获批上市，更早为本土患者带来了新的治疗选择。 顾军教授的报告引发了与会专家的热烈响应。同济大学附属皮肤病医院邹颖教授表示，从顾军教授分享 的患者照片中可以清晰看到其止痒效果的显著改善，使用泽立美后患者搔抓行为明显减少。邹颖教授强 调："泽立美在儿童疗效和安全性方面的优势，为临床医生提供了传统非激素药物外的全新选择，丰富 了治疗策略，可以帮助患者更好地管理病情。" 会上，杭州市第三人民医院刘苏俊教授在《特应性皮炎外用药治疗新进展》报告中指出，与此前获批用 于治疗银屑病的药物不同，泽立美专为AD设计，基于AhR调节的创新机制，展现出巨大的治疗潜力， 为医生提供了新的药物选择。 近日，备受瞩目的2025年中国中西医结合学会皮肤性病专业委员会学术年会在上海举办。本次年会围绕 皮肤性病领域的前沿进展、中西医结合特色疗法等议题展开了深入交流与探讨。作为一种特应性皮炎 (AD)新药，泽立美以其独特作用机制，为AD ...